Being diagnosed with breast cancer is undoubtedly challenging, but it also presents a unique opportunity to better understand the immune system's role in health and disease.

Our latest article explores how immune fitness can provide valuable insights in this context.

Cancer immune response meets longevity

Check it out here: lnkd.in/dE_qmFJn

👇👇👇👇👇👇 Let me explain below 1/13

Our previous research has shown that the 14-gene B-cell signature, IGG, is highly prognostic in breast cancer, especially in HER2+ and TNBC.

Interestingly, IGG consistently shows a strong link with both relapse and overall survival (OS).

We believed this OS association stemmed from IGG detecting fewer distant recurrences—which is partially true. But there's more...👇👇👇

📢 I am very happy to announce that the HER2DX genomic test for patients with early-stage HER2+ breast cancer is officially available at @RevealGenomics!

See thread below where I explain story + details behind HER2DX 👇

@OncoAlert @_SEOM @myESMO @ASEICAnews @_SOLTI @GEICAM #COI HER2DX is the consequence of >10 years of research in HER2+ breast cancer (by many researchers, not only me/us!)

In 2012, I was a postdoc at Charles M. Perou Lab (bit.ly/3Ku9nn0) @UNC_Lineberger

Yes, I had more hair👱, and I "pipetted"🧪🧑‍🔬